Michael Boice has over 20 years of experience in translational oncology drug development, from bench science to business development. As Senior Director, Scientific Engagement and Key Accounts at Certis Oncology Solutions, Michael works directly with biopharmaceutical clients to enhance their preclinical programs through a collaborative approach to scientific problemsolving and optimized study designs. Michaels areas of expertise include the development of novel oncology therapeutics, functional genomics, and rare cancers. He holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences, Department of Pharmacology Memorial Sloan Kettering Cancer Center, Cancer Biology and Genetics.
AIenabled Outcome Predictions and Personalized Orthotopic PDX Models
Predictive AI has tremendous potential in personalized cancer treatment, particularly where combinatorial therapies are of interest. But, reliably validating in silico predictions remains a challenge. Learn how one ongoing clinical research study is tackling this issue using orthotopic patientderived xenograft (OPDX) modelspersonalized mouse avatars of patientparticipants.
AI and Data Sciences Showcase:
Certis Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence™ — highly predictive therapeutic response data derived from AI-enabled insights and validated in advanced biological models of cancer.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2023 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.